Cystatin c and cystatin glomerular filtration rate as markers of early renal disease in asian indian subjects with glucose intolerance (CURES-32)

Metabolic Syndrome and Related Disorders

Volumn 7, Issue 5, 2009, Pages 419-426

  Surendar, J ^a   Anuradha, S ^a   Ashley, Berty ^a   Balasubramanyam, M ^a   Aravindhan, V ^a   Rema, M ^a   Mohan, V ^a  

^a MADRAS DIABETES RESEARCH FOUNDATION   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTATIN C;

ADULT; ARTICLE; ASIAN; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE MARKER; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE INTOLERANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

ADULT; ALBUMINURIA; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CHOLESTEROL; CYSTATIN C; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; EARLY DIAGNOSIS; GLOMERULAR FILTRATION RATE; GLUCOSE INTOLERANCE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INDIA; MIDDLE AGED; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; UP-REGULATION;

EID: 70350323488     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2008.0084     Document Type: Article

References (51)

1. Brancati FL, Whelton PK, Randall BL, Neaton JD, Stamler J, Klag MJ. Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT, Multiple Risk Factor Intervention Trial. JAMA 1997;278:2069-2074.
2. Chowdhury TA, Barnett AH, Bain SC. Pathogenesis of diabetic nephropathy. Trends Endocrinol Metabol 1996;7:320-323.
3. Brown SC, O'Reilly PH. Iohexol clearance for the determination of glomerular fi ltration rate in clinical practice: evidence for a new gold standard. J Urol 1991;146:675-679.
4. Young DS. Effects of Drugs on Clinical Laboratory Tests, 2nd ed. Washington DC: AACC Press 1990.
5. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 1992;38:1933-1953.
6. Krolewski AS, Warram JH. Natural history of diabetic nephropathy. Diabetes Rev 1995;3:446-459.
7. Denium J, Derkx FHM. Cystatin for estimation of glomerular fi ltration rate? Lancet 2000;356:1624-1625.
8. Coll E, Botey A, Alvarez L, Poch E, Quintó L, Saurina A, Vera M, Piera C, Darnell A. Serum cystatin C as a new marker for noninvasive estimation of glomerular fi ltration rate and as a marker for early impairment. Am J Kidney Dis 2000;36:29-34.
9. Risch L, Blumberg A, Huber A. Rapid and accurate assessment of glomerular fi ltration rate in patients with renal transplants using serum cystatin C. Nephrol Dialysis Transpl 1991;14:1991-1996.
10. Kazama JJ, Kutsuwada K, Ataka K, Maruyama H, Gejyo F. Serum cystatin C reliably detects renal dysfunction in patients with various renal diseases. Nephron 2002;91:13-20.
11. Piwowar A, Knapik-Kordecka M, Buczynska H, Warwas M. Plasma cystatin C concentration in non-insulin-dependent diabetes mellitus: Relation with nephropathy. Archivum Immunologiae Et Therapiae Experimentalis 1999;47:327-331.
12. Sicree R, Shaw J, Zimmet P. Diabetes and impaired glucose tolerance. In Diabetes Atlas. International Diabetes Federation, 3rd ed. Gan D, ed. Belgium: International Diabetes Federation 2006:15-103.
13. Samanta A, Burden AC, Feehally J, Walls J. Diabetic renal disease: differences between Asian and white patients. Br Med J (Clinical Research Ed) 1986;293:366-367.
14. Mather HM, Chaturvedi N, Fuller JH. Mortality and morbidity from diabetes in South Asians and Europeans: 11-year follow- up of the Southall Diabetes Survey, London, UK. Diabetic Med 1998;15:53-59.
15. Chandie Shaw PK, Baboe F, Van Es LA, Van Der Vijver JC, van de Ree MA, de Jonge N, Rabelink TJ. South-Asian type 2 diabetic patients have higher incidence and faster progression of renal disease compared with Dutch-European diabetic patients. Diabetes Care 2006;29:1383-1385.
16. Unnikrishnan RI, Rema M, Pradeepa R, Deepa M, Shanthirani CS, Deepa R, Mohan V. Prevalence and risk factors of diabetic nephropathy in an urban South Indian population: the Chennai Urban Rural Epidemiology Study (CURES 45). Diabetes Care 2007;30:2019-2024.
17. Deepa M, Pradeepa R, Rema M, Anjana RM, Deepa R, Shanthirani S, Mohan V. The Chennai Urban Rural Epidemiology Study (CURES)-study design and methodology (urban component) (CURES-I). J Assn Physicians India 2003;51:863-870.
18. Rema M, Mohan V, Deepa R, Ravikumar R. Association of carotid intima-media thickness and arterial stiffness with diabetic retinopathy: The Chennai Urban Rural Epidemiology Study (CURES-2). Diabetes Care 2004;27:1962-1967.
19. Rema M, Premkumar S, Anitha B, Deepa R, Pradeepa R, Mohan V. Prevalence of diabetic retinopathy in urban India: the Chennai Urban Rural Epidemiology Study (CURES) eye study I. Invest Ophthalmol Visual Sci 2005;46:2328-2333. (Pubitemid 43119476)
20. Varghese A, Deepa R, Rema M, Mohan V. Prevalence of microalbuminuria in type 2 diabetes mellitus at a diabetes centre in southern India. Postgrad Med J 2001;77:399-402.
21. Early Treatment of Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic colour fundus photographs:an extension of the modifi ed Airlie House classifi cation. ETDRS report number. Ophthalmology 1991;98: 786-806.
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
24. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular fi ltration rate from serum creatinine: a new prediction equation. Modifi cation of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470.
25. Macisaac RJ, Tsalamandris C, Thomas MC, Premaratne E, Panagiotopoulos S, Smith TJ, Poon A, Jenkins MA, Ratnaike SI, Power DA, Jerums G. Estimating glomerular fi ltration rate in diabetes: a comparison of cystatin-C and creatinine-based methods. Diabetologia 2006;49:1686-1689.
26. Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis 2001;37:79-83.
27. Randers E, Erlandsen EJ, Pedersen OL, Hasling C, Danielsen H. Serum cystatin C as an endogenous parameter of the renal function in patients with normal to moderately impaired kidney function. Clin Nephrol 2000;54:203-209.
28. Meir P, Froidevaux C, Dayer E, Blanc E. Cystatin C concentration and glomerular fi ltration rate. Lancet 2001;357:634-635.
29. Herget-Rosenthal S, Trabold S, Pietruck F, Heemann U, Philipp T, Kribben A. Cystatin C: Effi cacy as screening test for reduced glomerular fi ltration rate. Am J Nephrol 2000;20:97-102.
30. Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, Price CP. Serum cystatin C: a replacement for creatinine as a biochemical marker for GFR. Kidney Int 1994;47(suppl):20-21.
31. Oddoze C, Morange S, Portugal H, Berland Y, Dussol B. Cystatin C is not more sensitive than creatinine for detecting early renal impairment in patients with diabetes. Am J Kidney Dis 2001;38:310-316.
32. Finney H, Newman DJ, Price CP. Adult reference ranges for serum cystatin C, creatinine and predicted creatinine clearance. Ann Clin Biochem 2000;37(Pt 1):49-59.
33. Randers E, Krue S, Erlandsen EJ, Danielsen H, Hansen LG. Reference interval for serum cystatin C in children. Clin Chem 1999;45:1856-1858.
34. Baylis C, Schmidt R. The aging glomerulus. Semin Nephrol 1996;16:265-276.
35. Strevens H, Wide-Swensson D, Grubb A, Hansen A, Horn T, Ingemarsson I, Larsen S, Nyengaard JR, Torffvit O, Willner J, Olsen S. Serum cystatin C refl ects glomerular endotheliosis in normal, hypertensive and pre-eclamptic pregnancies. Br J Obstetr Gynaecol 2003;110:825-830.
36. Larsson A, Helmersson J, Hansson LO, Basu S. Serum cystatin C is associated with other cardiovascular risk markers and cardiovascular disease in elderly men. Int J Cardiol 2008;125: 263-264.
37. Haffner SM. Impaired glucose tolerance, insulin resistance and cardiovascular disease. Diabetic Med 1997;14(Suppl 3):12-18.
38. Ebrahimian TG, Tamarat R, Clergue M, Duriez M, Levy BI, Silvestre JS. Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice. Arterioscler Thromb Vasc Biol 2005;25:65-70.
39. Horie K, Miyata T, Maeda K, Miyata S, Sugiyama S, Sakai H, van Ypersole de Strihou C, Monnier VM, Witztum JL, Kurokawa K. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in thepathogenesis of diabetic nephropathy. J Clin Investig 1997;100:2995-2999.
40. Pandolfi A, Cetrullo D, Polishuck R, Alberta MM, Calafi ore A, Pellegrini G, Vitacolonna E, Capani F, Consoli A. Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects. Arterioscler Thromb Vasc Biol 2001;21:1378-1382.
41. Hofmann MA, Schiekofer S, Kanitz M, Klevesath MS, Joswig M, Lee V, Morcos M, Tritschler H, Ziegler R, Wahl P, Bierhaus A, Nawroth PP. Insuffi cient glycemic control increases nuclear factor-kappa B binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes. Diabetes Care 1998;21:1310-1316.
42. Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metab 2000;85:2970-2973.
43. Portilla D, Dai G, Peters JM, Gonzalez FJ, Crew MD, Proia AD. Etomoxir-induced PPARalpha-modulated enzymes protect during acute renalfailure. Am J Physiol-Renal Physiol 2000;278: 667-675.
44. Felaco M, Grilli A, De Lutiis MA, Patruno A, Libertini N, Taccardi AA, Di Napoli P, Di Giulio C, Barbacane R, Conti P. Endothelial nitric oxide synthase (eNOS) expression and localization in healthy and diabetic rat hearts. Ann Clin Lab Sci 2001;31:179-186.
45. Studer RK, Craven PA, DeRubertis FR. Role for protein kinase C in the mediation of increased fi bronectin accumulation by mesangial cells grown in high-glucose medium. Diabetes 1993;42:118-126.
46. Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, King GL. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Investig 1997;100:115-126.
47. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002;288:2579-2588.
48. Adaikalakoteswari A, Balasubramanyam M, Rema M, Mohan V. Differential gene expression of NADPH oxidase (p22phox) and hemoxygenase-1 in patients with Type 2 diabetes and microangiopathy. Diabet Med 2006;23:666-674.
49. Williams B. A potential role for angiotensin II-induced vascular endothelial growth factor expression in the pathogenesis of diabetic nephropathy? Min Electrolyte Metabol 1998;24:400-405.
50. Thomas MC, Forbes JM, Cooper ME. Advanced glycation end products and diabetic nephropathy. Am J Therapeut 2005;12:562-572.
51. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225-232.